Feed aggregator

Resistance levels still high in bacteria causing foodborne infections

ECDC - News - Thu, 04/08/2021 - 15:00
A sizeable proportion of Salmonella and Campylobacter bacteria is still resistant to antibiotics commonly used in humans and animals, as in previous years, says a report released today by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
Categories: C.D.C. (Europe)

COVAX reaches over 100 economies, 42 days after first international delivery

WHO news - Thu, 04/08/2021 - 14:35
  • The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on 24 February 2021.
  • So far, more than 38 million doses of vaccines from manufacturers AstraZeneca, Pfizer-BioNTech and Serum Institute of India (SII) have now been delivered, including 61 economies eligible for vaccines through the Gavi COVAX Advance Market Commitment.
  • COVAX aims to supply vaccines to all participating economies that have requested vaccines, in the first half of 2021, despite some delays in planned deliveries for March and April.

More than one hundred economies have received life-saving COVID-19 vaccines from COVAX, the global mechanism for equitable access to COVID-19 vaccines. The milestone comes 42 days after the first COVAX doses were shipped and delivered internationally, to Ghana on 24 February 2021.

COVAX has now delivered more than 38 million doses across six continents, supplied by three manufacturers, AstraZeneca, Pfizer-BioNTech and the Serum Institute of India (SII). Of the over 100 economies reached, 61 are among the 92 lower-income economies receiving vaccines funded through the Gavi COVAX Advance Market Commitment (AMC).

Despite reduced supply availability in March and April – the result of vaccine manufacturers scaling and optimizing their production processes in the early phase of the rollout, as well as increased demand for COVID-19 vaccines in India – COVAX expects to deliver doses to all participating economies that have requested vaccines in the first half of the year.

“In under four months since the very first mass vaccination outside a clinical setting anywhere in the world, it is tremendously gratifying that the roll-out of COVAX doses has already reached one hundred countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “COVAX may be on track to deliver to all participating economies in the first half of the year yet we still face a daunting challenge as we seek to end the acute stage of the pandemic: we will only be safe when everybody is safe and our efforts to rapidly accelerate the volume of doses depend on the continued support of governments and vaccine manufacturers. As we continue with the largest and most rapid global vaccine rollout in history, this is no time for complacency.”

“COVAX has given the world the best way to ensure the fastest, most equitable rollout of safe and effective vaccines to all at-risk people in every country on the planet,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “If we are going to realize this great opportunity, countries, producers and the international system must come together to prioritize vaccine supply through COVAX. Our collective future, literally, depends on it.”

"This is a significant milestone in the fight against COVID-19. Faced with the rapid spread of COVID-19 variants, global access to vaccines is fundamentally important to reduce the prevalence of the disease, slow down viral mutation, and hasten the end of the pandemic,” said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI). “The extraordinary scientific achievements of the last year must now be matched by an unprecedented effort to protect the most vulnerable, so the global community must remain firmly focused on reducing the equity gap in COVID-19 vaccine distribution." 

“In just a month and a half, the ambition of granting countries access to COVID vaccines is becoming a reality, thanks to the outstanding work of our partners in the COVAX Facility,” said Henrietta Fore, UNICEF Executive Director. “However, this is no time to celebrate; it is time to accelerate. With variants emerging all over the world, we need to speed up global rollout. To do this, we need governments, along with other partners, to take necessary steps to increase supply, including by simplifying barriers to intellectual property rights, eliminating direct and indirect measures that restrict exports of COVID-19 vaccines, and donating excess vaccine doses as quickly as possible.”

According to its latest supply forecast, COVAX expects to deliver at least 2 billion doses of vaccines in 2021. In order to reach this goal, the COVAX Facility will continue to diversify its portfolio further, and will announce new agreements with vaccine manufacturers in due course. 

Furthermore, in March it was announced that the United States government will host the launch event for the 2021 Gavi COVAX AMC Invest Opportunity to catalyze further commitment and support for accelerated access to vaccines for AMC-supported economies. An additional US$ 2 billion is required in 2021 to finance and secure up to a total of 1.8 billion donor-funded doses of vaccines. COVAX is also working to secure additional sourcing of vaccines in the form of dose-sharing from higher income countries.

Quotes from donors and partners

President of the European Commission Ursula von der Leyen said: “As we continue our common race to speed up safe and effective vaccination everywhere, I want to commend COVAX for having delivered first vaccines to 100 countries in every corner of the world, including some of the most vulnerable warn torn countries like Afghanistan and Yemen. This is a real milestone. Team Europe has strongly invested in COVAX and I urge all partners to support COVAX to make sure no one is left behind”.  

Senator the Hon Marise Payne, Minister for Foreign Affairs and Minister for Women, Australia said: “Australia welcomes the progress made by COVAX in COVID-19 vaccine distribution across the world. One hundred countries now have access to life-saving COVID-19 vaccines through COVAX. We are proud to work with global partners to achieve equitable global access to safe and effective vaccines.”

Karina Gould, Minister of International Development, Canada and co-chair, COVAX AMC Engagement Group said: “Despite the many challenges it faced, the COVAX Facility has continued to deliver. In just a matter of weeks, it’s been supplying vaccines to 100 countries. This is a milestone we can all be proud of. Now, more than ever, we must continue to work together and support multilateral mechanisms like the COVAX Facility and the ACT-Accelerator.”  

Jean-Yves le Drian, Minister of Europe and Foreign Affairs, France said: “One hundred countries have now received safe, WHO-approved vaccines against COVID-19 through the COVAX Facility. France welcomes this crucial step forward, which demonstrates that multilateralism in global health, as well as the spirit of solidarity and responsibility on which it is based, constitutes the most effective response to this pandemic. But the fight against the virus is far from over: we must continue to support COVAX and accelerate equitable access to vaccines in fragile countries, in particular through sharing of vaccine doses. This is what France wants to do, together with its EU and G7 partners.”

Dr Gerd Müller, Federal Minister for Economic Cooperation and Development, Germany said: “We either beat the pandemic worldwide or we will not beat it at all. The only way out of the crisis is a global immunization campaign. In order to now be able to vaccinate people quickly, we are using the tried and tested structures of the global vaccine alliance Gavi. Thanks to the vaccination platform COVAX, the structures are in place to provide vaccines for at least 20 per cent of people in developing countries and emerging economies over the course of this year.”

Heiko Maas, Minister of Foreign Affairs, Germany said: “The fact that St.Lucia yesterday became the 100th country to be supplied with vaccines via the COVAX platform supported by Germany and the EU, is a milestone on the way out of the pandemic. This progress gives us hope, for we too will only be safe when everyone around the world is safe. Access to vaccines, medicines and tests must not become a geopolitical pawn. Rather, they must be available to all countries in a fair and transparent manner. That’s why we’re committed to COVAX, to a multilateral approach.”

Colm Brophy TD, Minister of State for Overseas Development and the Diaspora, Ireland said: “Through our funding to COVAX, Ireland is supporting developing countries, who most need vaccines and can least afford them, secure their share of global supply.”

Dag-Inge Ulstein, Minister of International Development, Norway, and Co-chair of the ACT-Accelerator Facilitation Council said: “In less than a year, the world has come together to develop and secure equitable global access to COVID-19 vaccines. That is a huge victory. But the risk of vaccine nationalism is still looming large. Countries and manufactures must prioritize global solutions. It is also crucial that all manufacturers continue to make their vaccines available and affordable to COVAX, so that the global rollout can continue. Countries that have more vaccines than they need should share vaccines through COVAX. I also expect all relevant stakeholders to take action to ensure that the world can produce enough vaccines, at a price that even the poorest countries can afford.”

H.E. Dr Tawfig AlRabiah, Minister of Health in Saudi Arabia said: “‘People’s health first’ has been the guiding principle, driving all efforts in the fight against the pandemic - both nationally and globally - to ensure that “No one is left behind”. We in the kingdom are proud contributors to GAVI and the COVAX facility, which has now shipped over 37 million vaccines. This show of solidarity is the cure to fighting COVID-19, and our collective resilience will enable us to overcome any future pandemic we may face.”  

Foreign, Commonwealth and Development Office Minister Wendy Morton, United Kingdom said: “From Nigeria to Nepal, COVAX has now delivered life-saving vaccine doses to 100 countries and territories which is a huge achievement and another step towards making us all safe. The UK has played a leading role in achieving equitable access to vaccines by providing £548 million for COVAX early on, which will help to deliver more than one billion doses around the world, as well as lobbying international partners to increase their funding.”

United States Secretary of State Antony J. Blinken said: “The United States welcomes the news that COVAX has delivered safe and effective COVID-19 vaccines to 100 countries.  The United States signaled our strong support for COVAX through an initial $2 billion contribution to Gavi.  Through unprecedented partnerships among donors, manufacturers, and participating countries, COVAX has achieved extraordinary milestones in equitably distributing doses to the global community in record time.” 

Werner Hoyer, President of the European Investment Bank said: “As part of Team Europe the European Investment Bank is pleased to provide EUR 400 million for COVAX, representing the EIB’s largest ever support for global public health. COVAX has already provided vaccines to vulnerable groups and front line workers and brought hope to millions more. COVAX demonstrates the benefit of global cooperation to tackle the shared challenge of COVID. Congratulations to the COVAX team and global partners in 100 countries around the world. Together we are ensuring equitable access to vaccines and together we are directing our efforts towards a global recovery.”

Pascal Soriot, AstraZeneca CEO, said: “Today marks a significant milestone in the global fight against the pandemic as 100 countries have received vaccine through COVAX. I am proud that the supply of our vaccine accounts for the vast majority of doses being delivered through COVAX in the first half of this year. Over 37 million doses of our vaccine have been delivered to date which are protecting the most vulnerable populations around the world.  Together with our COVAX partners, we continue to work 24/7 to deliver on our unwavering commitment to broad, equitable and affordable access.”

Pfizer Chairman and CEO Albert Bourla said: “Congratulations to everyone who has worked tirelessly to reach this impressive milestone. At Pfizer we are driven every day by the belief that science will win. Through collaboration and commitment, COVAX has brought forth a global solution that helps to bring breakthrough science to everyone, everywhere. We are proud to work together with the facility and all of its partners and remain firmly committed to working toward the shared vision of equitable access for all to end this pandemic.” 

Sai D. Prasad, President, Developing Countries Vaccines Manufacturing Network (DCVMN) said: “COVAX has made history by ensuring equitable access for COVID-19 vaccines to all countries irrespective of their economic status. The 100th delivery marks a great milestone for COVAX, leading to enhanced deliveries during 2021. We commend the efforts by all partners in COVAX for this achievement. Developed and developing country manufacturers have played a crucial role in product development and large scale manufacturing. In order to meet the requirements of all countries, more partnerships between innovators and manufacturers are required. COVAX’s leadership in COVID-19 vaccines will ensure that we leave no one behind.”

Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) & founding partner of ACT-A said: “The timeline is truly impressive. It's an innovation success story with the first WHO vaccine approval on 31 December 2020, less than a year after the virus was first shared.  It’s a manufacturing success story with the scaling up from zero to one billion doses being produced by April 2021.  It is a logistics and country preparedness success story, with 100 countries receiving the vaccines and last but by no means least, it's a collaboration and solidarity success story, thanks to the commitment from donors and the tireless efforts of the partners of COVAX including the developing and the developed world manufacturers. COVAX’s partnerships together with political leadership to equitably share surplus vaccines are the best guarantees we have that people who need the vaccine will get it whenever they live, fast enough to outpace the virus’ mutations.”

Notes to editors

The list of 102 Facility participants (as of 14h CET, 8 April) that have received a combined total of 38,392,540 doses of COVAX-delivered vaccines so far is as follows (in alphabetical order):

Afghanistan, Albania, Algeria, Andorra, Angola, Argentina, Armenia, Azerbaijan, Bahamas, Bahrain, Barbados, Belize, Benin, Bermuda, Bolivia (Plurinational State of), Bosnia and Herzegovina, Botswana, Brazil, Brunei Darussalam, Cabo Verde, Cambodia, Canada, Colombia, Congo (DRC), Costa Rica, Côte d'Ivoire, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Eswatini, Ethiopia, Fiji, Gambia, Georgia, Ghana, Grenada, Guatemala, Guyana, Honduras, India, Indonesia, Iran (Islamic Republic of), Iraq, Jamaica, Jordan, Kenya, Kosovo, Lao People's Democratic Republic, Lebanon, Lesotho, Liberia, Malawi, Maldives, Mali, Mauritius, Mongolia, Montenegro, Morocco, Mozambique, Nauru, Nepal, Nicaragua, Nigeria, North Macedonia, Oman, Palestine, Paraguay, Peru, Philippines, Qatar, Republic of Korea, Republic of Moldova, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sri Lanka, St. Lucia*, Sudan, Suriname, Taiwan, Tajikistan, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Tuvalu, Uganda, Uruguay, Uzbekistan, Viet Nam, Yemen. 

*100th Facility participant to receive a COVAX delivery 

About COVAX 

COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-convened by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance) and the World Health Organization (WHO) – working in partnership with UNICEF as key implementing partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.

CEPI’s role in COVAX

CEPI is leading on the COVAX vaccine research and development portfolio, investing in R&D across a variety of promising candidates, with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future.  

Gavi’s role in COVAX

Gavi is leading on procurement and delivery at scale for COVAX: coordinating the design, implementation and administration of the COVAX Facility and the COVAX AMC and working with its Alliance partners UNICEF and WHO, along with governments, on country readiness and delivery. As part of this role, Gavi hosts the Office of the COVAX Facility to coordinate the operation and governance of the mechanism as a whole, manages relationships with Facility participants, and negotiates advance purchase agreements with manufacturers of promising vaccine candidates on behalf of the 190 economies participating in the COVAX Facility. It also coordinates design, operation and fundraising for the COVAX AMC that supports 92 lower-income economies, including a no-fault compensation mechanism that will be administered by WHO. As part of this work, Gavi supports governments and partners on ensuring country readiness, providing funding and oversight of UNICEF procurement of vaccines as well as partners’ and governments work on readiness and delivery. This includes support for cold chain equipment, technical assistance, syringes, vehicles, and other aspects of the vastly complex logistical operation for delivery.

WHO’s role in COVAX

WHO has multiple roles within COVAX: It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. Its Strategic Advisory Group of Experts (SAGE) on Immunization develops evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL)/prequalification programmes ensure harmonized review and authorization across member states. It provides global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provides R&D technical coordination. WHO leads, together with UNICEF, the Country Readiness and Delivery workstream, which provides support to countries as they prepare to receive and administer vaccines. Along with Gavi and numerous other partners working at the global, regional, and country-level, the CRD workstream provides tools, guidance, monitoring, and on the ground technical assistance for the planning and roll-out of the vaccines. Along with COVAX partners, WHO has developed a no-fault compensation scheme as part of the time-limited indemnification and liability commitments.

UNICEF’s role in COVAX

UNICEF is leveraging its experience as the largest single vaccine buyer in the world and working with manufacturers and partners on the procurement of COVID-19 vaccine doses, as well as freight, logistics and storage. UNICEF already procures more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries. In collaboration with the PAHO Revolving Fund, UNICEF is leading efforts to procure and supply doses of COVID-19 vaccines for COVAX. In addition, UNICEF, Gavi and WHO are working with governments around the clock to ensure that countries are ready to receive the vaccines, with appropriate cold chain equipment in place and health workers trained to dispense them. UNICEF is also playing a lead role in efforts to foster trust in vaccines, delivering vaccine confidence communications and tracking and addressing misinformation around the world.

About ACT-Accelerator

The Access to COVID-19 Tools ACT-Accelerator, is a new, ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March 2020 and launched by the WHO, European Commission, France and The Bill & Melinda Gates Foundation in April 2020. 

The ACT-Accelerator is not a decision-making body or a new organization, but works to speed up collaborative efforts among existing organizations to end the pandemic. It is a framework for collaboration that has been designed to bring key players around the table with the goal of ending the pandemic as quickly as possible through the accelerated development, equitable allocation, and scaled up delivery of tests, treatments and vaccines, thereby protecting health systems and restoring societies and economies in the near term. It draws on the experience of leading global health organizations which are tackling the world’s toughest health challenges, and who, by working together, are able to unlock new and more ambitious results against COVID-19. Its members share a commitment to ensure all people have access to all the tools needed to defeat COVID-19 and to work with unprecedented levels of partnership to achieve it.

The ACT-Accelerator has four areas of work: diagnostics, therapeutics, vaccines and the health system connector. Cross-cutting all of these is the workstream on Access & Allocation. 

WHO launches Progress Indicators to measure access to assistive technology

WHO news - Thu, 04/08/2021 - 11:21

Today, 1 billion people globally need assistive technology to lead healthy, productive and dignified lives but only 1 in 10 have access. One of the biggest barriers to accessing assistive technology is a lack of data. Without relevant, quality information, decision makers face huge challenges in developing evidence-informed policies and programmes to improve access for their populations.

The  resolution on improving access to assistive technology (resolution WHA71.8) urges all Member States to take actions to improve access to assistive technology, and requests the World Health Organization (WHO) to develop a Global Report on Assistive Technology based on the best available scientific evidence and international experience.

WHO has developed the WHA71.8 Progress Indicators for access to assistive technology to collect high-level information from all Member States to track and measure progress in achieving the resolution. The Progress Indicators monitor the status of assistive technology access across ten specific areas reported in the resolution: legislation, population and geographic coverage, budget, responsible ministries, human resources, education and training, financial coverage, regulations and standards, and specific assistive technology initiatives. 

Data will be collected between April and June 2021, and will be reported in the Global Report on Assistive Technology presented at the Seventy-fifth World Health Assembly in 2022.

Information video on WHA71.8 Progress Indicators for access to assistive technology

 

COVID-19 Vaccination Toolkits

2019 Novel Coronavirus (CDC) - Thu, 04/08/2021 - 07:00
COVID-19 Vaccination Toolkits for Medical Centers, Clinics, and Pharmacies, Long-term Care Facilities, Essential Workers, Community Based Organizations
Categories: C.D.C. (U.S.)

COVID-19 Contact Tracing Communications Graphics

2019 Novel Coronavirus (CDC) - Thu, 04/08/2021 - 07:00
These graphics will help health departments develop their communications with communities about COVID-19 contact tracing.
Categories: C.D.C. (U.S.)

Post-COVID Conditions: Information for Healthcare Providers

2019 Novel Coronavirus (CDC) - Thu, 04/08/2021 - 07:00
CDC is working to learn more about the range of short- and long-term health effects associated with COVID-19. While most persons with COVID-19 recover and return to normal health, some patients can have symptoms that can last for weeks or even months after recovery from acute illness. Even people who are not hospitalized and who have mild illness can experience persistent or late symptoms. Multi-year studies are underway to further investigate. CDC continues work to identify how common these symptoms are, who is most likely to get them, and whether these symptoms eventually resolve.
Categories: C.D.C. (U.S.)

Late Sequelae of COVID-19

2019 Novel Coronavirus (CDC) - Thu, 04/08/2021 - 07:00
Late Sequelae of COVID-19
Categories: C.D.C. (U.S.)

Long-Term Effects of COVID-19

2019 Novel Coronavirus (CDC) - Thu, 04/08/2021 - 07:00
Heart conditions associated with COVID-19 include inflammation and damage to the heart muscle itself, known as myocarditis, or inflammation of the covering of the heart, known as pericarditis.
Categories: C.D.C. (U.S.)

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine

WHO news - Wed, 04/07/2021 - 18:17

The COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) has reviewed reports of rare cases of blood clots with low platelets following vaccination with the AstraZeneca COVID-19 vaccine (including Covishield) since their onset a few weeks ago.

At its most recent meeting on 7 April, 2021, the subcommittee reviewed latest information from the European Medicines Agency along with information from the United Kingdom’s Medicines and other Health products Regulatory Agency (MHRA), and other Member States and noted the following:

  • Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors.
  • The GACVS subcommittee will continue to gather and review further data, as it has done since the beginning of the COVID vaccine programme.
  • It is important to note that whilst concerning, the events under assessment are very rare, with low numbers reported among the almost 200 million individuals who have received the AstraZeneca COVID-19 vaccine around the world.
  • Rare adverse events following immunizations should be assessed against the risk of deaths from COVID-19 disease and the potential of the vaccines to prevent infections and reduce deaths due to diseases. In this context, it should be noted that as of today, at least 2.86 million people have died of COVID-19 disease worldwide.
  • Side effects within two- or three-days following vaccination, the majority of which are mild and local in nature, are expected and common. However, individuals who experience any severe symptoms – such as shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms, such as severe and persistent headaches or blurred vision, tiny blood spots under the skin beyond the site of the injection - from around four to 20 days following vaccination, should seek urgent medical attention. Clinicians should be aware of relevant case definitions and clinical guidance for patients presenting thrombosis and thrombocytopaenia following COVID-19 vaccination. To this end, the GACVS subcommittee also suggested that a committee of clinical experts including haematologists and other specialists is convened, for advice on clinical diagnosis and case management. 
  • Active surveillance, including sentinel site / hospital case-based investigations should be considered, to further characterise these rare events. WHO has developed template protocols that countries could adapt for such studies. The GACVS will meet again next week to review additional data and will be issuing further recommendations as relevant

WHO is carefully monitoring the rollout of all COVID-19 vaccines and will continue to work closely with countries to manage potential risks, and to use science and data to drive response and recommendations.

In extensive vaccination campaigns, it is normal for countries to identify potential adverse events following immunization. This does not necessarily mean that the events are linked to vaccination itself, but they must be investigated to ensure that any safety concerns are addressed quickly. Vaccines, like all medicines, can have side effects. The administration of vaccines is based on a risk versus benefit analysis.

Alisson Becker and WHO Foundation launch campaign to raise resources and support treatment for COVID-19 patients starting in the Americas

WHO news - Wed, 04/07/2021 - 18:05

“Give a Breath for Health” campaign launched on World Health Day to kickstart global effort for purchasing oxygen and other life-saving supplies and therapeutics

Champion goalkeeper Alisson Becker, World Health Organization (WHO) Goodwill ambassador for health promotion, is kickstarting a new global fundraising campaign, titled “Give a Breath for Health,” driven by the WHO Foundation and WHO. The initiative aims to support the delivery of oxygen and other life-saving supplies to health facilities treating patients with COVID-19 around the world.

The first donation to the “Give a Breath for Health” campaign, made by Alisson, will contribute with supplies to locations in the Amazon and collaborate with the efforts of the Pan American Health Organization (PAHO), WHO regional office for the Americas, in support of the Ministry of Health of Brazil and the State Health Department of Amazonas.

“I am a proud Brazilian and wish my people the best health possible. Working together we can overcome this difficult moment and I will do what I can to help my country, my Region, and the world, during the COVID-19 crisis,” said Alisson, goalkeeper for the Brazilian national football team and Liverpool Football Club. “While vaccines offer great hope to many countries around the world, there remains a desperate need in many areas for supplies of essential medicines and equipment, including oxygen, to help keep people alive in our hospitals and clinics.” 

Part of Alisson’s contribution will be used to purchase non-invasive ventilation masks for people hospitalized in remote parts of Brazil due to COVID-19. The supplies will be delivered to eight municipalities in the state of Amazonas: Coari, Humaitá, Itacoatiara, Lábrea Parintins, São Gabriel da Cachoeira, Tabatinga and Tefé.

The rest of the donation will be used to purchase equipment to fill oxygen cylinders in the municipality of Tabatinga, located on the border with Colombia and Peru. These supplies will help solve a logistical problem regarding the need to send the cylinders to other locations for refilling.

“We are concerned about the situation in the Americas, where a surge in COVID-19 cases is causing some areas to experience very high occupancy rates at intensive care units and putting health systems at risk of collapsing,” said PAHO Director, Carissa F. Etienne. “As more and more patients require hospitalization, solidarity response efforts like the one led by Alisson Becker can help provide health care workers in the Region with much-needed supplies and equipment, including oxygen, to save lives.”

Oxygen delivery is among the priorities identified in WHO’s recently released Strategic Preparedness and Response Plan for 2021, for which the COVID-19 Solidarity Response Fund is seeking to raise funds from individuals, philanthropies, and corporates.

Anil Soni, Chief Executive Officer of the WHO Foundation, thanked Alisson Becker for his generous support to health facilities in the Americas and for being the driving force behind the “Give a Breath for Health” campaign.

“The response to COVID-19 is bigger than any one country or government can manage alone.  The ‘Give a Breath for Health’ campaign is an exciting example of how the COVID-19 Solidarity Response Fund can enable anyone, anywhere to support the urgently needed pandemic response efforts of WHO and its partners.”

 

About the WHO Foundation

The WHO Foundation is an independent grant-making foundation, based in Geneva, that sets out to protect the health and well-being of everyone in every part of the world, working alongside the World Health Organization and the global health community. It aims to support donors, scientists, experts, implementing partners, and advocates around the world in rapidly finding new and better solutions to the most pressing global health challenges of today and tomorrow.

The Foundation targets evidence-based initiatives that support WHO in delivering Sustainable Development Goal (SDG) 3 (To ensure healthy lives and promote well-being for all). It is focused on reducing health risks, averting pandemics, better managing diseases, and creating stronger health systems. It tackles these areas by building awareness and supporting its partners, including WHO, so that every life is invested in and the world is ready for any health emergency that may arise.

WHO Foundation. Together we have so much to achieve.

www.who.foundation

Campaign website 

About PAHO

PAHO works with the countries of the Americas to improve the health and quality of life of the population. Founded in 1902, it is the oldest international public health organization in the world. It serves as the WHO regional office for the Americas and is the specialized health agency of the inter-American system. More information at www.paho.org

 

Nigerian Youth Call for Action to Improve Adolescents' Health

Maternal, newborn and child health - Wed, 04/07/2021 - 12:29
Deliberations center on revitalizing healthcare services threatened by COVID- 19

Marking the World Health Day, youth leaders and civil society groups from across Nigeria are urging the government to invest in equity enhancing strategies to restore crumbling services for women, newborns, children and adolescents.

World Health Day: Building Forward Fairer for Vulnerable Women, Children and Adolescents

Maternal, newborn and child health - Wed, 04/07/2021 - 12:29
Helga Fogstad, Executive Director & Etienne Langlois, Team Lead, Knowledge

This year's World Health Day, celebrated on 7th of April, focuses on the critical need to enhance equity for the most vulnerable communities worldwide. COVID-19 has further highlighted this need, given it is unravelling the hard-fought gains made over recent decades in reducing maternal, newborn and child mortality. During 2020, coverage of lifesaving health interventions for women, children and adolescents in 36 developing countries was estimated to have dropped by up to 25%. Recent UNFPA estimates indicate that across 115 low- and middle-income countries, the pandemic disrupted contraceptive use for about 12 million women, causing nearly 1.4 million unintended pregnancies in 2020. Similarly, according to a UNICEF, WHO and Gavi pulse survey, three-quarters of 82 surveyed countries reported COVID-19-related disruptions to immunization programmes.

People with Moderate to Severe Asthma

2019 Novel Coronavirus (CDC) - Wed, 04/07/2021 - 07:00
COVID-19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack, and possibly lead to pneumonia and acute respiratory disease.
Categories: C.D.C. (U.S.)

Engaging Community Health Workers to Support Home-based care for people with COVID-19 in low-resource settings

2019 Novel Coronavirus (CDC) - Wed, 04/07/2021 - 07:00
This document provides suggestions for how Community Health Workers can support home-based care in low resource settings, including different actions community health workers can take to support patients, their families, and their communities during COVID-19, and how to identify which people are eligible for home-based care.
Categories: C.D.C. (U.S.)

COVID-19 Employer Information for Office Buildings

2019 Novel Coronavirus (CDC) - Wed, 04/07/2021 - 07:00
Learn how office building employers, building owners and managers, and building operations specialists can create a safe and healthy workplace for workers and clients.
Categories: C.D.C. (U.S.)

Teachers and Staff Resuming In-Person Learning

2019 Novel Coronavirus (CDC) - Wed, 04/07/2021 - 07:00
As your school resumes in-person learning during the coronavirus pandemic - whether for the first time or following an outbreak - this page can help you identify ways to protect your own health, as well as the health of students in your classroom.
Categories: C.D.C. (U.S.)

Vaccine Adverse Event Reporting System (VAERS)

2019 Novel Coronavirus (CDC) - Wed, 04/07/2021 - 07:00
VAERS is an early warning system used to monitor adverse events that happen after vaccination.
Categories: C.D.C. (U.S.)

WHO urges countries to build a fairer, healthier world post-COVID-19

WHO news - Tue, 04/06/2021 - 12:34
For World Health Day, 7 April 2021, WHO is issuing five calls for urgent action to improve health for all people.

Essential Services and Critical Infrastructure

2019 Novel Coronavirus (CDC) - Tue, 04/06/2021 - 07:00
Essential Services and Critical Infrastructure
Categories: C.D.C. (U.S.)

How to Select, Wear, and Clean Your Mask

2019 Novel Coronavirus (CDC) - Tue, 04/06/2021 - 07:00
COVID-19 spreads mainly from person to person through respiratory droplets produced when an infected person coughs, sneezes, or talks. These droplets can land in the mouths or noses of people who are nearby or possibly be inhaled into the lungs.
Categories: C.D.C. (U.S.)

Pages

Subscribe to Brain Association Iasi aggregator